Norditropin Daily denied for missing prior authorization by UnitedHealthcare?

UnitedHealthcare requires prior authorization for Norditropin (daily somatropin) under its Commercial growth hormone policy, and defines an "essential" use of growth hormone as therapy to treat a deficiency as part of chronic disease management, distinguishing it from non-essential replacement uses . Covered indications follow FDA labeling and include Congenital Growth Hormone Deficiency (GHD), Pediatric GHD, Transition Phase Adolescent GHD, Adult GHD, and Prader-Willi Syndrome , with additional pediatric indications such as short stature born small for gestational age (SGA) with no catch-up growth by age 2 to 4, and Idiopathic Short Stature (ISS) with height SDS less than -2.25 and growth rates unlikely to permit attainment of adult height in the normal range . Authorization is issued for 12 months at a time , and for transition adolescents the criteria apply during the period from mid to late teens until 6 to 7 years after achievement of adult height . Contraindications per labeling include acute critical illness after open heart or abdominal surgery or multiple accidental trauma, pediatric patients with Prader-Willi syndrome who are severely obese or have upper airway obstruction/sleep apnea, hypersensitivity to somatropin or excipients, and active proliferative or severe non-proliferative diabetic retinopathy . Benefit caps may apply: if the diagnosis is essential the cap is overridden, but if non-essential only the authorization applies and supply limits may be in place . Adult GHD diagnosis typically requires biochemical confirmation (e.g., Insulin Tolerance Test less than 5 ng/mL as the test of choice ) and an endocrinologist must coordinate therapy.

- Submit complete biochemical workup: two failed GH provocative stimulation tests for pediatric GHD per Pediatric Endocrine Society (Grimberg et al., 2016) guidelines, or for adults the Endocrine Society 2011 guideline (Molitch et al.) and AACE/ACE 2019 guideline ( College of endocrinology guidelines for management of growth hormone deficiency in adults and patients transitioning from pediatric to adult care, Endocr Pract 2019;25(11):1191-1232 ) which support diagnosis with documented pituitary/hypothalamic disease plus low IGF-1 - Provide growth charts demonstrating height SDS and growth velocity, citing Pediatric Endocrine Society guidelines providing recommendations for the clinical management of children and adolescents with growth failure ; if transition-age, cite AACE 2019 transition guidance for retesting - Document open epiphyses by X-ray and ongoing growth velocity >2 cm/year, or document clinical reason for slower response (e.g., late puberty), aligned with Pediatric Endocrine Society recommendations - Confirm prescription is written or co-managed by a board-certified endocrinologist with attestation letter - Demonstrate that contraindications do not apply (e.g., negative sleep study and BMI documentation for PWS patients, ophthalmologic clearance for diabetics, no active neoplasm) per Norditropin prescribing information - Argue essential-use designation: GHD as replacement for a chronic pituitary disease meets UHC's own definition of "therapy to treat a deficiency as part of chronic disease management" , which should override benefit caps - For adult continuation, submit IGF-1 normalization, improvement in body composition, lipid profile, and quality-of-life scores (AGHDA) supporting clinical benefit per Endocrine Society guideline ( Molitch ME et al., Evaluation and treatment of adult growth hormone deficiency: an Endocrine Society clinical practice guideline, J Clin Endocrinol Metab )

## Why UnitedHealthcare Demands PA on Norditropin Daily

UnitedHealthcare's Commercial Medical Benefit Drug Policy for somatropin (covering Norditropin, Genotropin, Humatrope, Nutropin AQ, Omnitrope, Saizen, Zomacton) treats growth hormone as a high-cost specialty drug with a structural "essential vs. non-essential" gate. The PA-required denial is not a substantive coverage decision — it is a procedural placeholder that triggers until the prescriber submits clinical documentation through OptumRx (pharmacy benefit) or the medical-benefit notification portal (when billed as a J-code under HCPCS J2941). Knowing which channel applies is half the appeal: Norditropin self-injected at home almost always adjudicates under the OptumRx pharmacy benefit, routed through BriovaRx/Optum Specialty Pharmacy, not the medical side.

### The Documentation UHC Actually Wants

The policy maps directly to FDA labeling. For Adult GHD, UHC will not accept a clinical impression — it wants a biochemical confirmation, with the Insulin Tolerance Test (ITT) peak GH <5 ng/mL named as the test of choice (glucagon stim or macimorelin are acceptable surrogates when ITT is contraindicated). For Pediatric GHD, two provocative stim tests are standard, plus bone age, growth velocity charts, and IGF-1/IGFBP-3. For ISS, the height SDS threshold is <−2.25 with documented inability to reach normal adult height. For SGA, no catch-up by age 2–4. Transition adolescents require re-testing after final height attainment — UHC explicitly limits authorization to the window from mid-to-late teens until 6–7 years post-final-height. Authorizations issue in 12-month increments, so anticipate a re-PA at month 11.

### Procedural Leverage

Most PA-required denials at UHC fail because the submission omits the IGF-1 trend, the prescriber is not a board-certified endocrinologist, or the stim-test result was not attached as a discrete lab document. Resubmit through the OptumRx PA portal (covermymeds.com or 1-800-711-4555) with: (1) endocrinologist note, (2) provocative testing results with peak values, (3) MRI of pituitary (for organic GHD), (4) growth chart with calculated velocity (pediatric), and (5) attestation that no contraindication exists (no active malignancy, no acute critical illness post-surgery, no PWS with severe obesity/OSA, no active diabetic retinopathy).

If denied on "medical necessity" after the PA is submitted, ERISA §503-1 (29 CFR §2560.503-1) entitles you to the full claim file, including the reviewer's credentials and the internal clinical guideline applied. Pinto v. Aetna (10th Cir. 2014) establishes the insurer's burden to show a treatment is experimental — flip the script and force UHC to defend why FDA-labeled use fails its own policy. For self-funded ERISA plans, escalate to external review under 29 USC §1185d once internal levels exhaust; for fully-insured plans, file with the state DOI in parallel.

Tactical tip: Before resubmitting, call OptumRx and ask the rep to read back the exact PA criteria checklist the reviewer used — UHC reviewers work from a binary clinical decision tree, and one missing data element (typically the discrete stim-test PDF or the endocrinologist's NPI taxonomy code 207RE0101X) triggers auto-denial. Fix that single defect and the second submission usually clears within 72 hours.